使用纳米载体对胰腺β细胞进行1型糖尿病治疗的积极向
Jillian Collins1, Nikki L Farnsworth2
1Department of Chemical and Biological Engineering, Colorado School of Mines, Golden, CO, USA.
开发针对1型糖尿病的向疗法需要识别特定的β细胞标记物. 纳米载体与新型向技术相结合,为保护和再生胰腺β细胞提供了一个有希望的方法,改善了治疗结果.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 纳米技术纳米技术
- 药物运输 药物运输 药物运输
背景情况:
- 1型糖尿病是一种自身免疫性疾病,导致胰腺β细胞的破坏,导致胰岛素依赖.
- 目前的胰岛素治疗可以控制血糖,但不能防止β细胞死亡或促进再生.
- 针对β细胞保存或增殖的现有治疗方法可能会由于异于目标的作用而引起副作用.
研究的目的:
- 审查纳米载体用于1型糖尿病的向输送的应用.
- 突出目前β细胞向策略的现状.
- 确定新的β细胞特异性标记物,以加强治疗开发.
主要方法:
- 探索基于纳米载体的药物递送系统,以准β细胞.
- 审查用于识别β细胞特异性标的技术,包括SELEX受体选择和菌体显示查.
- 利用人类样本的OMIC数据集来发现新的β细胞标记物.
主要成果:
- 纳米载体显示出克服目前1型糖尿病治疗方法的局限性的潜力.
- 一个重大挑战是缺乏高特异性的β细胞标记物,用于向治疗的开发.
- 先进的查技术对于识别合适的β细胞标至关重要.
结论:
- 使用纳米载体的β细胞向疗法代表了1型糖尿病治疗的重大进步.
- 识别特定的β细胞标记物对于开发定制治疗非常重要.
- 这种方法有可能阻止疾病的进展,甚至可以逆转1型糖尿病.
更多相关视频
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
16:59Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer
Published on: October 10, 2012
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Insulin Secretory Vesicles
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
